Navigation Links
SMA Foundation and Rules-Based Medicine Collaborate on Biomarker Panels to Guide SMA Therapeutic Development
Date:1/19/2011

NEW YORK and AUSTIN, Texas, Jan. 19, 2011 /PRNewswire/ -- The Spinal Muscular Atrophy (SMA) Foundation and Rules-Based Medicine, Inc. (RBM) announced today that they have reached the first milestone in a program to develop a panel of plasma protein biomarkers for SMA using RBM's Multi-Analyte Profiling (MAP) technology platform.  In this collaboration, RBM will discover and also confirm plasma protein biomarker candidates previously identified from the multicenter Biomarkers for SMA (BforSMA) clinical study sponsored by the SMA Foundation and conducted by BG Medicine. The identification of such biomarkers may help to assess drug efficacy and shorten the duration of clinical trials of SMA therapies.

In this initial stage of the collaboration, the SMA Foundation provided BforSMA plasma samples to RBM for processing on the DiscoveryMAP™ platform plus an additional set of 70 biomarker assays.  Candidate biomarkers were found that significantly differentiated between disease and control groups and correlated with SMA disease severity.  The SMA Foundation and RBM are continuing to analyze these results and plan to create a specific panel of biomarker assays for use in clinical trials exploring new treatments for SMA.

"Biomarkers are critical to accelerating therapeutic development for any disease. They are even more important for rare diseases like SMA where patient populations are small and mostly consist of children," said Karen Chen, Ph.D., Chief Scientific Officer of the SMA Foundation. "We are excited to work with RBM to leverage their MAP technology to develop a biomarker panel for SMA that will help evaluate responses to treatments more efficiently and minimize the burden of clinical trials for patients and families."

"We are delighted to support the efforts of the SMA Foundation to develop better treatments for this tragic disease," said Craig Benson, Chief Executive Officer of RBM.  "Our MAP technology has been effective as part of many therapeutic development programs and for identifying biomarker patterns linked to complex diseases.  The confirmation and validation of biomarker patterns on our platform and the availability of testing services through our CLIA-certified lab will accelerate the development of new treatments for SMA."

About Rules-Based Medicine (RBM)

Rules-Based Medicine's biomarker testing service provides clinical researchers, physicians and healthcare providers with reproducible, quantitative, multiplexed data for hundreds of proteins to advance drug development and patient care. The Company's proprietary Multi Analyte Profiling (MAP) technology offers pre-clinical and clinical researchers broad, cost-effective protein analyses in multiple species from a small sample volume. MAP technology also supports RBM's drive to develop diagnostics that aid in the detection of complex diseases and conditions in areas of unmet medical need such as neuropsychiatry, nephrology, immunology and cardiology. RBM's initial molecular diagnostic test, VeriPsych™, is a blood-based test that aids in the confirmation of diagnosis of recent-onset schizophrenia by evaluating a proprietary set of 51 biomarkers. RBM also offers innovative and proprietary ex vivo testing systems such as TruCulture™, the first fully-closed, reproducible whole blood culture system. More information about RBM is located at www.rulesbasedmedicine.com

ABOUT SPINAL MUSCULAR ATROPHY

Spinal Muscular Atrophy (SMA) is a motor neuron disease and the leading genetic cause of death among infants and toddlers.  Characterized by selective loss of nerve cells in the spinal cord, the disease leads to increasing muscular weakness and atrophy. Patients afflicted by SMA lose muscle control and strength, leading to progressive inability to walk, stand, sit up and breathe, depending on the severity of the disease. It is estimated that approximately 1 in 6,000 -10,000 infants are born annually worldwide with SMA.

ABOUT THE SPINAL MUSCULAR ATROPHY FOUNDATION

Founded in 2003, the Spinal Muscular Atrophy Foundation is a nonprofit organization dedicated to accelerating progress towards a treatment and cure for spinal muscular atrophy through targeted funding of clinical research and novel drug development efforts.  Since its inception, the Foundation has awarded over $60 million in sponsored research agreements.  In addition, the Foundation is committed to raising awareness and generating support for increased research efforts in SMA among the leaders of industry and government.  For more information on the Spinal Muscular Atrophy Foundation, visit www.smafoundation.org or call (646) 253-7100.


'/>"/>
SOURCE Spinal Muscular Atrophy Foundation; Rules-Based Medicine, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. IDRI Awarded Grant from Bill and Melinda Gates Foundation to Identify Candidates for Novel TB Drugs
2. Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
3. MinuteClinic Becomes First Retail Clinic Provider to Launch Partnership with National Patient Safety Foundation for Ask Me 3™ Program
4. Teach For America and the Amgen Foundation Renew Partnership to Improve Math and Science Education in Urban and Rural Schools
5. Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinsons Disease
6. The Citizen CPR Foundation Launches National Call to Action to Empower Citizens to Save Lives of Those with Sudden Cardiac Arrest
7. Amgen Foundation and Ashokas Changemakers Announce Finalists in Patients
8. Choices
9. Empowerment Competition
10. VIDEO from International Osteoporosis Foundation available on thenewsmarket.com: IOF Focuses on WHO Fracture Risk Assessment Tool for International Discussions
11. Higher Education Foundation in Brazil Seals Its Continued Relationship with Thomson Reuters for Academic Healthcare Content
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... , Jan. 16, 2017  This report by ... central catheters market for the period 2016–2024. The ... updates and information related to market opportunities in ... comprehensive market study demonstrates the various dynamics that ... future status of the global peripherally inserted central ...
(Date:1/16/2017)... , Jan. 16, 2017 Derek ... Potts Law Firm, was recently appointed Liaison Counsel in ... (JCCP) for all Xarelto cases. In this role, Potts ... parties and will actively assist the Court and Co ... with Milstein Adelman Jackson Fairchild & ...
(Date:1/16/2017)... 2017  According to Kalorama Information, the global ... at $4.9 billion for 2016.  The growing number ... aging population with significant diagnostic needs, along with ... the market for the modality.  The healthcare market ... focuses on the worldwide market, providing market size ...
Breaking Medicine Technology:
(Date:1/15/2017)... , ... January 15, 2017 , ... ... Community Outreach is a program that strives to better communities around the world ... locations’ community. It also provides the opportunity for team members to become involved ...
(Date:1/15/2017)... ... 2017 , ... Accreditation Commission for Health Care (ACHC) is ... services. Albertsons Companies is the largest national food and drug chain with ... Accreditation by ACHC reflects Albertsons Companies’ dedication and commitment to meeting national standards ...
(Date:1/15/2017)... ... January 15, 2017 , ... ... best physicians in eight Bay Area counties for 2017. Almost 1,000 nominations were ... company managing the award process. Results were announced the magazine’s January 2017 ...
(Date:1/15/2017)... ... ... The Gravity Vault Indoor Rock Climbing Gym is excited to announce the ... 14,000+ square foot climbing gym, the owners anticipate to open sometime in February 2017. ... two in New York. With this being its first location in Pennsylvania, The Gravity ...
(Date:1/14/2017)... MN (PRWEB) , ... January 14, 2017 , ... ... present the distinctions among their expanding line of activated charcoal products. With more ... the importance of categorizing their products according to how they cater to specific ...
Breaking Medicine News(10 mins):